BEAT Key Statistics, Chart & Performance
The current stock price of BEAT is 2.49 USD. In the past month the price increased by 223.38%. In the past year, price increased by 11.16%.
BEAT Latest News, Press Relases and Analysis
BEAT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.96 | 216.61B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.83 | 203.98B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.46 | 141.96B | ||
| SYK | STRYKER CORP | 26.77 | 134.80B | ||
| BDX | BECTON DICKINSON AND CO | 13.53 | 55.70B | ||
| IDXX | IDEXX LABORATORIES INC | 54.55 | 54.93B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.83 | 50.45B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.12 | 37.88B | ||
| RMD | RESMED INC | 24.53 | 35.45B | ||
| DXCM | DEXCOM INC | 36.27 | 26.31B | ||
| PODD | INSULET CORP | 62.88 | 20.22B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.19 | 17.94B |
Related stock screener links
About BEAT
Company Profile
HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. The company is headquartered in Santa Clara, California and currently employs 16 full-time employees. The company went IPO on 2021-10-14. The firm focuses on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. The company is engaged in the development of higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented electrocardiography technology platform. The company is developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms. The company is developing its own product, the HeartBeam System. The HeartBeam System comprises a credit card sized 12-lead output electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. The core technology consists of a series of patented inventions that allow it to capture the heart’s electrical activity from three distinct directions.
Company Info
HEARTBEAM INC
2118 Walsh Ave., Suite 210
Santa Clara CALIFORNIA 19355 US
CEO: Joseph H. Capper
Employees: 16
Phone: 14088994443
HEARTBEAM INC / BEAT FAQ
What does BEAT do?
HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. The company is headquartered in Santa Clara, California and currently employs 16 full-time employees. The company went IPO on 2021-10-14. The firm focuses on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. The company is engaged in the development of higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented electrocardiography technology platform. The company is developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms. The company is developing its own product, the HeartBeam System. The HeartBeam System comprises a credit card sized 12-lead output electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. The core technology consists of a series of patented inventions that allow it to capture the heart’s electrical activity from three distinct directions.
What is the stock price of HEARTBEAM INC today?
The current stock price of BEAT is 2.49 USD. The price increased by 2.05% in the last trading session.
Does HEARTBEAM INC pay dividends?
BEAT does not pay a dividend.
What is the ChartMill technical and fundamental rating of BEAT stock?
BEAT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists BEAT stock?
BEAT stock is listed on the Nasdaq exchange.
How is the market expecting BEAT stock to perform?
9 analysts have analysed BEAT and the average price target is 4.72 USD. This implies a price increase of 89.46% is expected in the next year compared to the current price of 2.49.
Is HEARTBEAM INC (BEAT) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BEAT.
BEAT Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to BEAT. When comparing the yearly performance of all stocks, BEAT is one of the better performing stocks in the market, outperforming 85% of all stocks.
BEAT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BEAT. While BEAT seems to be doing ok healthwise, there are quite some concerns on its profitability.
BEAT Financial Highlights
Over the last trailing twelve months BEAT reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS increased by 5.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -716.97% | ||
| ROE | -5078.82% | ||
| Debt/Equity | 0 |
BEAT Forecast & Estimates
9 analysts have analysed BEAT and the average price target is 4.72 USD. This implies a price increase of 89.46% is expected in the next year compared to the current price of 2.49.